- HETEROCYCLIC COMPOUNDS AND USES THEREOF
-
Provided herein are novel heterocyclic compounds, for example, compounds having Formula I, I-P, II, lI-P, or III. Also provided herein are pharmaceutical compositions comprising the compounds and methods of using the same, for example, in inhibiting aldehyde dehydrogenases and/or for treating various cancers, cancer metastasis, type 2 diabetes, pulmonary arterial hypertension (PAH) or neointimal hyperplasia (NIH).
- -
-
Paragraph 0390
(2021/07/31)
-
- Synthesis and characterization of the anticancer and metal binding properties of novel pyrimidinylhydrazone derivatives
-
Three novel pyrimidinylhydrazones substituted at either the aromatic moiety or at the imine carbon atom were synthesized and characterized by standard analytical methods. All compounds were found to be toxic in the micro- to submicromolar range against a diverse panel of cancer cell lines including multidrug resistant (MDR) derivatives expressing P-glycoprotein (Pgp). UV-visible spectrophotometry experiments demonstrated that the most active compound (3) forms highly stable complexes with iron(III) and copper(II) in a wide pH range with a stronger preference towards iron(III). The redox activity of the iron and copper complexes of ligand 3 was investigated using cyclic voltammetry and was tested with cellular reductants. The impact of reactive oxygen species (ROS) on the mechanism of toxicity was assessed using the ROS-sensitive cell permeable dye 2′,7′-dichlorofluorescin diacetate (DCFDA). Our results demonstrate that the studied pyrimidinylhydrazones form redox-active iron and copper complexes that are capable of producing intracellular ROS, which might lead to cellular damage and cell death in cancer cells regardless of their resistance status.
- Pape, Veronika F.S.,Türk, Dra,Szab, Pl,Wiese, Michael,Enyedy, Eva A.,Szakcs, Gergely
-
-
- 5-lipoxygenase-activating protein (FLAP) inhibitors. Part 4: Development of 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin- 2-ylmethoxy)-1 H -indol-2-yl]-2,2-dimethylpropionic acid (AM803), a potent, oral, once daily FLAP inhibitor
-
The potent 5-lipoxygenase-activating protein (FLAP) inhibitor 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2- ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid 11cc is described (AM803, now GSK2190915). Building upon AM103 (1) (Hutchinson et al. J. Med Chem.2009, 52, 5803-5815; Stock et al. Bioorg. Med. Chem. Lett. 2010, 20, 213-217; Stock et al. Bioorg. Med. Chem. Lett.2010, 20, 4598-4601), SAR studies centering around the pyridine moiety led to the discovery of compounds that exhibit significantly increased potency in a human whole blood assay measuring LTB4 inhibition with longer drug preincubation times (15 min vs 5 h). Further studies identified 11cc with a potency of 2.9 nM in FLAP binding, an IC50 of 76 nM for inhibition of LTB4 in human blood (5 h incubation) and excellent preclinical toxicology and pharmacokinetics in rat and dog. 11cc also demonstrated an extended pharmacodynamic effect in a rodent bronchoalveolar lavage (BAL) model. This compound has successfully completed phase 1 clinical studies in healthy volunteers and is currently undergoing phase 2 trials in asthmatic patients.
- Stock, Nicholas S.,Bain, Gretchen,Zunic, Jasmine,Li, Yiwei,Ziff, Jeannie,Roppe, Jeffrey,Santini, Angelina,Darlington, Janice,Prodanovich, Pat,King, Christopher D.,Baccei, Christopher,Lee, Catherine,Rong, Haojing,Chapman, Charles,Broadhead, Alex,Lorrain, Dan,Correa, Lucia,Hutchinson, John H.,Evans, Jilly F.,Prasit, Peppi
-
experimental part
p. 8013 - 8029
(2012/03/08)
-
- Mononuclear iron complexes relevant to nonheme iron oxygenases. Synthesis, characterizations and reactivity of Fe-Oxo and Fe-Peroxo intermediates
-
The new ligand L624E (N,N,N′,N′- tetrakis(5-ethyl-2-pyridylmethyl)ethane-1,2-diamine) was designed as a more robust analog of TPEN (N,N,N′,N′-tetrakis(2-pyridylmethyl)ethane-1, 2-diamine) for which the ability at stabilizing high valent Fe-Oxo and Fe-(hydro)peroxo has been reported. With respect to the latter, the pyridyl β-substituents in L624E do not modify the Fe coordination chemistry. From the FeII precursor, [FeO]2+ and FeIII-(hydro)peroxo intermediates are prepared using the same synthetic methods as those reported for the TPEN analogs. The spectroscopic characteristics of all L624E-Fe complexes are very similar to their TPEN analog. However, [(L624E)FeO]2+ has a greater lifetime than that of [(TPEN)FeO]2+. This can be explained by a restricted bimolecular autodegradation due to the bulkiness provided by the ethyl substituents. Regarding small organic molecule oxidation, [(L624E)FeO]2+ and [(L6 24E)FeOOH]2+ exhibit behaviours that seem to be general for the complexes built with ligands of the TPEN family: [FeO]2+ appears to be efficient to epoxidize olefins, whereas [FeOOH]2+ hydroxylates the aromatic ring of anisole with efficacy. The Royal Society of Chemistry 2009.
- Thibon, Aurore,Bartoli, Jean-Franois,Bourcier, Sophie,Banse, Frederic
-
experimental part
p. 9587 - 9594
(2010/03/04)
-
- BASIC AMINE COMPOUND AND USE THEREOF
-
Novel amine compounds which are represented by the following formula (1) and efficacious against diseases such as a viral infectious disease with HIV, rheumatism, and cancer metastasis; typically, A 1 and A 2 represent a hydrogen atom or a substitutable monocyclic or polycyclic heteroaromatic ring and W represents a substitutable benzene ring or any group represented by the following formula (10) or (11): where X represents O, CH 2 , C(=O), NR 11 , or CHR 35 and D represents a group represented by the following formula (6): where Q represents a single bond, NR 12 , or a group represented by the formula (13): and Y represents a group represented by the following formula (7) : where z represents a substitutable monocyclic or polycyclic aromatic ring; and B represents -NR 25 R 26 ; and R 1 to R 26 in the above formulae represent a hydrogen atom, an alkyl group, an alkenyl group, or an alkynyl group.
- -
-
Page/Page column 39
(2010/11/24)
-
- Improved Synthesis of N1-Pyridylthiamine Pyrophosphate, a Coenzymatically Active Analog of Thiamine Pyrophosphate
-
Our previously published synthesis of the N1-pyridyl analog 1b of thiamine pyrophosphate is improved resulting in a remarkably higher yield.Key reaction of this new synthetic pathway is the oxidative degradation of 5-acetylpyridine 8 to the 5-carboxylic acid 11 via the pyridinium compound 10.Improved preparations of other intermediates are also described.The N1-pyridylthiamine pyrophosphate analog 1b has been separated and purified by ion exchange chromatography on Sephadex A-25.
- Neef, Holger,Golbik, Ralph,Fahlbusch, Baerbel,Schellenberger, Alfred
-
p. 913 - 916
(2007/10/02)
-
- KINETICS OF THE N OXIDATION OF SOME COMPOUNDS OF THE PYRIDINE SERIES WITH PERBENZOIC ACID IN CHLOROFORM AND AQUEOUS DIOXANE
-
A comparative study of the kinetics of the N oxidation of 19 derivatives of the pyridine series with perbenzoic acid in choroform and aqueous dioxane at 20, 25, 30, and 35 deg C was made.The rate constants, the parameters of the Arrhenius equation, and the activation energies of the N oxidation of the indicated monoazines were determined.The scale of the reactivities of the derivatives of the pyridine series was calculated within the framework of the Pearson hard-soft acid-base concept.
- Lohkov, R.E.
-
p. 264 - 271
(2007/10/02)
-
